Objective: Patients suffering from bacterial infections of the lungs are frequently treated by alternating or combining the inhaled antibiotics tobramycin (aminoglycoside) and colistimethate-sodium (CMS, i.e. polymyxin E). Therefore, patients might feel encouraged to mix solutions of both antibiotics in order to inhale the mixture in one single inhalation session. As the effects of preparing such a mixture on physical and chemical stability of the solution are not known, an evaluation was triggered. Methods: Vials of tobramycin solution (170 mg/1.7 ml) were mixed with reconstituted CMS (2 Mio. IU CMS dissolved in 4 ml of 0.9% saline) and physicochemically characterized with respect to osmolality, viscosity, surface tension and pH. Additionally, the tobramycin content and possible tobramycin related impurities were assayed by HPLC. Results and Conclusion: Mixtures of the antibiotics did not show obvious signs of physicochemical incompatibilities. However, the measured content of tobramycin in the mixture decreased to 70−75% of the initial amount within about 12 hours. Already 10 minutes after mixing a marked decrease of tobramycin content (approx. −7%) was observed indicating a fairly rapid reaction or decomposition immediately after preparation and during treatment. Therefore, mixing of tobramycin containing solutions with CMS prior to inhalation cannot be recommended. Background: Although guidelines recommend that all CF patients chronically infected with Pseudomonas aeruginosa are offered prophylactic nebulised antibiotics (including high dose tobramycin, HDNT) to limit exacerbations and slow the rate of decline in lung function, their use has only been evaluated in a clinically stable population. However, HDNT is expensive and in the UK is often used as second line therapy, when patients are unstable or deteriorating on other treatments. We wished to determine whether HDNT is still effective in this patient group. Method: We looked at the effect of HDNT in 54 patients in our adult clinic who were prescribed this as a second line treatment, comparing pre-treatment clinical parameters with those for the subsequent 3 years. Forty were also taking nebulised colomycin in the month off HDNT.
